DJIA 18,135.72 38.82 0.21%
NASDAQ 4,982.81 15.67 0.32%
S&P 500 2,101.04 2.51 0.12%
market minute promo

CLOVIS ONCOLOGY INC (NASDAQ: CLVS)

79.66 2.26 (2.92%)

REAL-TIME: Last trade at

Extended Hours: $79.65 -$0.01 (-0.01%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

CLVS $79.66 2.92%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $77.84
Previous Close $77.40
Daily Range $77.00 - $80.38
52-Week Range $35.33 - $93.33
Market Cap $2.7B
P/E Ratio -16.40
Dividend (Yield) $0.00 (0.0%)
Volume 884,694
Average Daily Volume 459,466
Current FY EPS -$7.55

Sector

Industry

CLOVIS ONCOLOGY INC (CLVS) Description

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets. Website: http://www.clovisoncology.com/

News & Commentary Rss Feed

3 Beaten Down Biotech Stocks to Buy Now

The share prices of Dynavax Technologies, CellDex Therapeutics, and Clovis Oncology have all plunged this year. Here is why I think these beaten down biotechs are now compelling buys.

Clovis Oncology's (CLVS) CEO Patrick Mahaffy on Q4 2014 Results - Earnings Call Transcript

InsiderInsights.com Daily Round Up 1/20/15: WIW, WIA, OPK, MLNK

Clovis Oncology, Inc. (CLVS) in Focus: Stock Jumps 5.9% - Tale of the Tape

AstraZeneca's Lynparza Approved in EU for Ovarian Cancer - Analyst Blog

CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucap

CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data

Morning Market Losers

Clovis Lung Cancer Update Swings Momentum to Rival, Slightly

Clovis Oncology Enters Into Oncology Clinical Trial Collaboration With GlaxoSmithKline

Clovis Oncology (CLVS) Shares Cross Below 200 DMA

Clovis Oncology's (CLVS) CEO Presents at Credit Suisse 2014 Healthcare Conference (Transcript)

See More CLVS News...